Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) has received a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.

Analysts have set a one year consensus target price of $23.33 for the company and are expecting that the company will post ($0.65) EPS for the current quarter, according to Zacks. Zacks has also assigned Catabasis Pharmaceuticls an industry rank of 92 out of 265 based on the ratings given to related companies.

Several brokerages have recently commented on CATB. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $28.00 target price on shares of Catabasis Pharmaceuticls in a research report on Wednesday, May 25th. Zacks Investment Research cut Catabasis Pharmaceuticls from a “buy” rating to a “hold” rating in a research report on Monday, July 18th. Wedbush reaffirmed an “outperform” rating and issued a $17.00 target price on shares of Catabasis Pharmaceuticls in a research report on Friday, August 12th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Catabasis Pharmaceuticls in a research report on Wednesday, June 8th.

Catabasis Pharmaceuticls (NASDAQ:CATB) traded up 0.0025% during midday trading on Monday, hitting $3.9901. The stock had a trading volume of 1,700 shares. Catabasis Pharmaceuticls has a 12-month low of $3.31 and a 12-month high of $11.45. The stock’s market cap is $61.37 million. The company’s 50-day moving average price is $4.65 and its 200 day moving average price is $4.89.

Catabasis Pharmaceuticls (NASDAQ:CATB) last issued its earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.04. On average, equities research analysts predict that Catabasis Pharmaceuticls will post ($2.47) earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in CATB. Bridgeway Capital Management Inc. purchased a new stake in Catabasis Pharmaceuticls during the second quarter worth about $102,000. Sphera Funds Management LTD. boosted its stake in Catabasis Pharmaceuticls by 184.9% in the first quarter. Sphera Funds Management LTD. now owns 230,041 shares of the company’s stock worth $1,159,000 after buying an additional 149,299 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB boosted its stake in Catabasis Pharmaceuticls by 12.7% in the first quarter. Rhenman & Partners Asset Management AB now owns 345,100 shares of the company’s stock worth $1,739,000 after buying an additional 38,873 shares during the last quarter. 66.58% of the stock is owned by hedge funds and other institutional investors.

Catabasis Pharmaceuticls Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

5 Day Chart for NASDAQ:CATB

Get a free copy of the Zacks research report on Catabasis Pharmaceuticls (CATB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.